Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of PTC Therapeutics (NASDAQ: PTCT) (“PTC” or the “Company”). The investigations concern whether certain of the Company’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of PTC’s business practices.

Current stockholders of PTC that seek more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey Norton (jnorton@nfllp.com) or Benjamin Baker (bbaker@nfllp.com) to discuss this investigation and their rights.

Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907006236/en/